Pacific Edge Future Growth

Future criteria checks 0/6

Pacific Edge is forecast to grow earnings at 8.2% per annum. EPS is expected to grow by 24.7% per annum.

Key information

8.2%

Earnings growth rate

24.7%

EPS growth rate

Biotechs earnings growth	16.0%
Revenue growth rate	n/a
Future return on equity	-77.4%
Analyst coverage	Low
Last updated	21 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

ASX:PEB - Analysts future estimates and past financials data (NZD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	29	-30	-27	-26	N/A
12/31/2023	28	-31	-28	-26	N/A
9/30/2023	26	-32	-29	-27	N/A
6/30/2023	23	-29	-29	-26	N/A
3/31/2023	21	-27	-28	-26	N/A
12/31/2022	19	-24	-27	-24	N/A
9/30/2022	16	-21	-25	-23	N/A
6/30/2022	15	-21	-22	-20	N/A
3/31/2022	13	-20	-19	-18	N/A
12/31/2021	12	-18	-17	-16	N/A
9/30/2021	12	-16	-15	-15	N/A
6/30/2021	10	-15	-15	-14	N/A
3/31/2021	9	-14	-14	-14	N/A
12/31/2020	7	-15	-15	-15	N/A
9/30/2020	6	-17	-16	-16	N/A
6/30/2020	5	-18	-16	-16	N/A
3/31/2020	5	-19	-16	-15	N/A
12/31/2019	5	-19	-16	-16	N/A
9/30/2019	5	-19	-16	-16	N/A
6/30/2019	5	-18	-17	-17	N/A
3/31/2019	5	-18	-18	-18	N/A
12/31/2018	5	-18	-17	-17	N/A
9/30/2018	5	-18	-17	-17	N/A
6/30/2018	5	-19	-18	-17	N/A
3/31/2018	5	-20	-18	-18	N/A
12/31/2017	4	-20	N/A	-19	N/A
9/30/2017	3	-21	N/A	-19	N/A
6/30/2017	4	-22	N/A	-18	N/A
3/31/2017	4	-23	N/A	-18	N/A
12/31/2016	6	-21	N/A	-18	N/A
9/30/2016	8	-20	N/A	-17	N/A
6/30/2016	7	-18	N/A	-17	N/A
3/31/2016	6	-16	N/A	-17	N/A
12/31/2015	5	-15	N/A	-16	N/A
9/30/2015	4	-15	N/A	-16	N/A
6/30/2015	4	-14	N/A	-14	N/A
3/31/2015	3	-12	N/A	-13	N/A
12/31/2014	3	-11	N/A	-12	N/A
9/30/2014	2	-10	N/A	-11	N/A
6/30/2014	1	-10	N/A	-10	N/A
3/31/2014	1	-10	N/A	-10	N/A
12/31/2013	0	-9	N/A	-9	N/A
9/30/2013	0	-9	N/A	-8	N/A
6/30/2013	0	-8	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PEB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PEB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PEB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PEB's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if PEB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PEB is forecast to be unprofitable in 3 years.

Pacific Edge Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Recent updates

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Insufficient new directors

Pacific Edge Limited Announces Board Changes

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Independent Non-Executive Director recently bought AU$2.8m worth of stock

Key Executive recently bought AU$50k worth of stock

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

New minor risk - Market cap size

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Full year 2022 earnings released: NZ$0.026 loss per share (vs NZ$0.02 loss in FY 2021)

Now 20% undervalued after recent price drop

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Insufficient new directors

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Forecast to breakeven in 2023

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies